Publications by authors named "Moniquea Williams"
Article Synopsis
- The study examined the effectiveness of enzalutamide combined with immunotherapy in treating non-metastatic castration-sensitive prostate cancer (nmCSPC) without using androgen deprivation therapy (ADT).
- Patients with rising PSA levels were randomized to receive either enzalutamide alone or alongside PROSTVAC, showing significant PSA declines of 99% across both groups.
- Enzalutamide treatment led to immune system changes, including increased natural killer and naïve T cells, and was generally well-tolerated, with the most common side effects being mild fatigue and breast tenderness.
Objective: To evaluate the safety and efficacy of cabozantinib combined with docetaxel.
Patients And Methods: This was a phase 1/2 multicentre study in patients with metastatic castration-resistant prostate cancer (mCRPC). Docetaxel (75 mg/m every 3 weeks with daily prednisone 10 mg) was combined with escalating doses of daily cabozantinib (20, 40 and 60 mg).